- Thinly traded nano cap Neuralstem (CUR -1.8%) provides the latest example of the dangers of chasing "big pops" in biotech. The stock has completely retraced its 59% move on January 10 stoked by the issuance of a new patent covering its stem cells. Shares are currently exchanging hands at ~$3.79, slightly below the close of $3.81 on January 9.
- Other recent "big pops" have also given up much of their gains: GenVec (GNVC -10.8%), down 47% from its 1/10 peak; Signal Genetics (SGNL +1.2%), down 41% from its 1/11 peak; EnteroMediics (ETRM -37%), down 82% from its 1/10 peak and Transgenomic (TBIO -15.3%), down 49% from its 1/13 peak.